

Olga Lomovskaya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1742828/publications.pdf>

Version: 2024-02-01

26
papers

3,247
citations

331670

21
h-index

552781

26
g-index

26
all docs

26
docs citations

26
times ranked

2808
citing authors

#	ARTICLE	IF	CITATIONS
1	The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant <i>Enterobacterales</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0216821.	3.2	11
2	Predictive Rules of Efflux Inhibition and Avoidance in <i>Pseudomonas aeruginosa</i> . <i>MBio</i> , 2021, 12, .	4.1	28
3	<i>In Vitro</i> Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	16
4	QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. <i>Frontiers in Microbiology</i> , 2021, 12, 697180.	3.5	25
5	Structural Basis and Binding Kinetics of Vaborbactam in Class A β -Lactamase Inhibition. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
6	<i>In Vitro</i> Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
7	Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	31
8	<i>In Vitro</i> Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant <i>Enterobacterales</i> with Varying Intrinsic and Acquired Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	25
9	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo- β -lactamases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7491-7507.	6.4	135
10	Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	72
11	Biochemical Activity of Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	48
12	Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	32
13	Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in <i>Enterobacteriaceae</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	36
14	<i>In Vitro</i> Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	102
15	Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	28
16	Effect and Safety of Meropenem+Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections: The TANGO II Randomized Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2018, 7, 439-455.	4.0	313
17	Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	126
18	Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	255

#	ARTICLE	IF	CITATIONS
19	Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of <i>Klebsiella pneumoniae</i> with Increased Efflux Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	121
20	Discovery of a Cyclic Boronic Acid β -Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3682-3692.	6.4	331
21	Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in <i>Pseudomonas aeruginosa</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2755-2758.	2.2	91
22	Peptidomimetics of Efflux Pump Inhibitors Potentiate the Activity of Levofloxacin in <i>Pseudomonas aeruginosa</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 763-766.	2.2	77
23	Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in <i>Pseudomonas aeruginosa</i> : Novel Agents for Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 105-116.	3.2	804
24	Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in <i>Pseudomonas aeruginosa</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 663-667.	2.2	77
25	Use of a Genetic Approach To Evaluate the Consequences of Inhibition of Efflux Pumps in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1340-1346.	3.2	195
26	Inhibitors of Efflux Pumps in <i>Pseudomonas aeruginosa</i> Potentiate the Activity of the Fluoroquinolone Antibacterial Levofloxacin. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4928-4931.	6.4	245